Azitra reports FY2025 net loss of $11.0M, cash $2.1M; pipeline advances

Azitra, Inc.

2025-FY EPS reported -$2.25 vs consensus -$0.33 ▼ miss (-578.7%)

Net loss widened to $11.0M in FY2025 from $9.0M in FY2024; R&D $4.8M, G&A $6.2M.
Cash and equivalents of $2.1M as of Dec 31, 2025; completed $8.5M in financings during the year.
First patient dosed in Phase 1/2 trial for ATR-04 (EGFRi rash); Fast Track from FDA.
Topline data expected H2 2026 for ATR-12 (Netherton syndrome) and mid-2026 for ATR-04.
Positive preclinical data for ATR-01 (ichthyosis vulgaris); IND-enabling studies continue in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.